Lara Goldstein

Cybin Becomes International Leader in Psychedelic Therapeutics with Small Pharma Acquisition

Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have successfully completed their acquisition agreement, solidifying Cybin's position as a leader in the psychedelics sector. As a result of the acquisition, Small Pharma is now a wholly-owned...

Exploring the Power of Psychedelics: Jada Pinkett-Smith’s Ayahuasca Journey, Farewell to Dr. Roland Griffiths, and Congressional Veterans Affairs Hearings on Hold

Jada Pinkett Smith overcomes depression and suicidal thoughts with Ayahuasca Joining a growing number of Hollywood celebrities, Jada Pinkett Smith recently opened up about her struggles with mental health and the transformative impact of psychedelic substances in finding relief....

Red Light Holland Subsidiary Receives U.S. Patent for 3D Movement Data in Psychedelic-Assisted Therapy

Canadian mushrooms producer Red Light Holland's wholly-owned tech subsidiary, Radix Motion, has been granted a U.S. patent for the use of human movement data in psychedelic-assisted therapy (PAT). This patent, attained through the USPTO's Patent Prosecution Highway (PTT)...

Bionomics Meets The FDA: Lead Drug Candidate For Social Anxiety Heads To Phase 3

Biopharma company Bionomics Ltd. BNOX announced that, following an end-of-Phase 2 meeting with the Food and Drug AdministrationΒ (FDA), the agency supports the entrance of lead drug asset BNC210 -a negative allosteric modulator-Β targeting acute treatment of Social Anxiety Disorder (SAD)...

Lucy Scientific’s Fiscal Year: Operating Expenses Soar as Accumulated Deficit Surpasses $44 Million

Lucy Scientific Discovery (NASDAQ:LSDI) Reports FY 2023 Full-Year Results Lucy Scientific Discovery Inc. (LSDI), a leading psychedelics company, has announced its full-year results for the period ending June 30, 2023. The financial report reveals significant developments: Total cash held increased...

Psyched: FDA Warning, DEA’s Telehealth Extension, CA Gov’s Veto, Congress On Kratom, M&As & More

Weighing In: Cybin and Small Pharma Approve Acquisition Resolution Investors in the clinical-stage psychedelics biotechs, Cybin Inc. (CYBN) and Small Pharma Inc. (DMTTF), have given the green light to the arrangement plan for Small Pharma's acquisition by Cybin. This...

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates

Cybin and Small Pharma Shareholders Approve Acquisition: Results and Expected Dates Psychedelics biotechs Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) recently held their respective annual general and special shareholders meetings on October 12. The voting results...

Steve Cohen Expands Biopharma Portfolio with Strategic Purchase of Bionomics Shares

Renowned billionaire investor and owner of the NY Mets, Steve Cohen, continues to show his support for the biopharmaceutical sector by purchasing over 119 million shares of Bionomics Limited, a leading clinical-stage biopharma company. This move further solidifies...

Cybin Successfully Completes Dosing in Phase 2 Study of CYB003 for Major Depressive Disorder Treatment

Cybin Inc. (NYSE: CYBN), a clinical-stage biotech company specializing in the development of innovative psychedelic-based mental health treatments, has reached a significant milestone by completing the dosing phase of its Phase 2 study on CYB003, a deuterated psilocybin...

atai Life Sciences Successfully Concludes Phase 1 Clinical Trial for Oral Film DMT Formulation

atai Life Sciences, a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker symbol ATAI, has announced the completion of its Phase 1 clinical study for VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT (dimethyltryptamine). The...